Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450606 | 1.00 | TYR (0.43) | TYRCASP1SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL19614847 | 1.00 | TYR (0.43) | TYRCASP1SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL28836516 | 0.88 | CASP1 (0.39) | CASP1TDP1ALDH1A1 | |
| SCHEMBL6808279 | 0.88 | CASP1 (0.39) | CASP1TDP1ALDH1A1 | |
| SCHEMBL28836514 | 0.88 | CASP1 (0.39) | CASP1TDP1ALDH1A1 | |
| SCHEMBL14862094 | 0.87 | BACE1 (0.40) | TYRCASP1TDP1ALDH1A1BACE1 | |
| SCHEMBL12285510 | 0.87 | BACE1 (0.40) | TYRCASP1TDP1ALDH1A1BACE1 | |
| SCHEMBL12245283 | 0.87 | BACE1 (0.40) | TYRCASP1TDP1ALDH1A1BACE1 | |
| SCHEMBL3302721 | 0.87 | TYR (0.41) | TYRSMN1; SMN2ALDH1A1PLA2G2APLA2G5 | |
| SCHEMBL10537510 | 0.86 | TSHR (0.42) | CASP1SMN1; SMN2TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456781-B1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | BAYER IP GMBH (DE) | 2017-06-21 | — | — | EP | claimed |
| US-9096639-B2 | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | claimed |
| US-20120232042-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-13 | — | — | US | claimed |
| EP-0877746-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-11-18 | — | — | EP | claimed |
| WO-1997027195-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-07-31 | — | — | WO | claimed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025111431-A1 | ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025111450-A1 | ANTI-CD74 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | disclosed |
| EP-4525928-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525927-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| WO-1997027195-A9 | PROCESS FOR PREPARING PURINE DERIVATIVES | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997027198-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027196-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027197-A1 | PROCESS FOR PREPARING GANCICLOVIR DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027194-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-07-31 | — | — | WO | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0694547-A2 | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative | F. Hoffmann-La Roche AG (CH) | 1996-01-31 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | TYR 4753/4885CASP1 193/4885SMN1; SMN2 644/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | TYR 4859/4885CASP1 755/4885SMN1; SMN2 1063/4885 |
| US-20120232042-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | CYP19A1, HSD17B11, SHBG | TYR 4278/4885CASP1 2172/4885SMN1; SMN2 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.